A Phase 3 interventional study of Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 38 sites in 4 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2017-05-12.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 25th largest by enrollment, is one of 8 that started in 2013, is one of 45 in phase 3, and was the 20th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 8 started in 2013.
This study's enrollment of 125 is above the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 40th largest by enrollment of the 116 interventional ones that give a count, is one of 11 that started in 2013, is one of 62 in phase 3, and was the 22nd registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and 113 (NCT01685801).
Ivacaftor is the first Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator to show an improvement in CFTR function and clinical benefit in participants with CF. Results from Phase 3 studies (NCT00909532 [Study 102] and NCT00909727 [Study 103]) showed that ivacaftor is effective in the treatment of participants with CF who have the G551D-CFTR mutation, as evidenced by sustained improvements in CFTR channel function (measured by reduction in sweat chloride concentration) and corresponding substantial, durable improvements in lung function, pulmonary exacerbations, respiratory symptoms, and weight gain. Ivacaftor was also well tolerated, as evidenced by the rates and reasons for premature discontinuation and results of safety assessments.
Ivacaftor (Trade Name Kalydeco; 150 mg tablets) was initially approved in the United States for the treatment of CF in participants 6 years of age and older who have a G551D mutation in the CFTR gene.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Ivacaftor Arm Only):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who received Ivacaftor 150 milligram (mg) tablet and/or Placebo matched to Ivacaftor tablet orally, every 12 hours (q12h) in the previous study VX11-770-110 (Study 110; NCT01614457), VX12-770-111 (Study 111; NCT01614470) or VX12-770-113 (Study 113; NCT01685801); received Ivacaftor 150 mg tablet q12h in this VX12-770-112 (Study 112; NCT01707290) up to 104 weeks.
Drug: Ivacaftor
Participants who received Ivacaftor 150 mg tablet and/or Placebo matched to Ivacaftor tablet, orally, q12h in the previous Study 110 (NCT01614457) or Study 111 (NCT01614470), were observed (did not receive study drug) in this Study 112 (NCT01707290) for up to 2 years.
150 mg tablet, oral use, every 12 hours (q12h)
Also known as: Kalydeco, VX-770
Number of Participants With Treatment Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs) in Ivacaftor Arm
AE: any untoward medical occurrence in a participants during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. TEAEs were defined as adverse events with start date or increased severity on and after the first dose of study drug through Week 108.
Time frame: Day 1 up to Week 108 (Study 112)
Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96, and 104
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 6 to 17 years and for female participants aged 6 to 15 years. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
Time frame: Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
Absolute Change From Baseline in Body Mass Index (BMI) at Week 2,12, 24, 36, 48, 60, 72, 84, 96 and 104
BMI was defined as weight in kg divided by height in m\^2. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
Time frame: Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
Absolute Change From Baseline in Sweat Chloride at Week 2, 24, 48 and 104
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
Time frame: Baseline, Week 2, 24, 48 and 104 (Study 112)
Absolute Change From Baseline in Respiratory Domain of the Cystic Fibrosis Questionnaire Revised (CFQ-R) at Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104
The CFQ-R is a validated participant reported outcome measuring health related quality of life for participants with CF. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health related quality of life. Baseline was defined as the most recent measurement before intake of the first dose of study drug (ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
Time frame: Baseline, Week 2, 12, 24, 36, 48, 60, 72, 84, 96 and 104 (Study 112)
Number of Pulmonary Exacerbations Events
Pulmonary exacerbation events include those events which require treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
Time frame: Through Week 104 (Study 112)
Number of Participants With Serious Adverse Events (SAEs) in Observational Arm
SAE was defined as a medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
Time frame: up to 2 years (Study 112)
| Milestone | Ivacaftor Arm | Observational Arm |
|---|---|---|
| Started | 121 | 4 |
| Completed | 35 | 3 |
| Not completed | 86 | 1 |
| Withdrew: Adverse event (ae) | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrawal of consent (not due to ae) | 4 | 0 |
| Withdrew: Commercial drug available | 60 | 1 |
| Withdrew: Other unspecified | 17 | 0 |
AE: any untoward medical occurrence in a participants during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after informed consent form is signed. AE includes serious as well as non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. TEAEs were defined as adverse events with start date or increased severity on and after the first dose of study drug through Week 108.
| participants | Ivacaftor Arm |
|---|---|
| Participants with TEAEs | 117 |
| Participants with SAEs | 27 |
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 6 to 17 years and for female participants aged 6 to 15 years. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
| Percent predicted of FEV1 | Ivacaftor Arm: Study 110 | Ivacaftor Arm: Study 111 | Ivacaftor Arm: Study 113 |
|---|---|---|---|
| Baseline | 71.8 ± 20.4 | 78.3 ± 21.1 | 62.8 ± 22.2 |
| Change at Week 2 | 3.8 ± 8 | 4.4 ± 7.7 | 4 ± 7.2 |
| Change at Week 12 | 5.4 ± 8.9 | 5.5 ± 8.3 | 4.9 ± 6.7 |
| Change at Week 24 | 4.5 ± 8.4 | 7.1 ± 8.3 | 4.6 ± 8.5 |
| Change at Week 36 | 4.4 ± 7.1 | 7.5 ± 8.2 | 4.9 ± 8.2 |
| Change at Week 48 | 4.4 ± 7.5 | 6.4 ± 10.7 | 4.9 ± 9 |
| Change at Week 60 | 4.5 ± 8.4 | 8.2 ± 8.3 | 4.5 ± 8.8 |
| Change at Week 72 | 3.6 ± 8.9 | 7.8 ± 9.2 | 5.9 ± 9.2 |
| Change at Week 84 | 5.4 ± 13.5 | 7.7 ± 7.6 | 4.8 ± 7.2 |
| Change at Week 96 | 4.1 ± 14.6 | 9.9 ± 6.4 | 5.9 ± 8.1 |
| Change at Week 104 | 4.6 ± 13.2 | 4.9 ± 5.8 | 6.3 ± 10 |
BMI was defined as weight in kg divided by height in m\^2. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
| kilogram per square meter (kg/m^2) | Ivacaftor Arm: Study 110 | Ivacaftor Arm: Study 111 | Ivacaftor Arm: Study 113 |
|---|---|---|---|
| Baseline | 23.75 ± 5.63 | 23.15 ± 5.28 | 24.81 ± 5.76 |
| Change at Week 2 | 0.06 ± 0.43 | 0.16 ± 0.47 | 0.07 ± 0.43 |
| Change at Week 12 | 0.32 ± 0.59 | 0.39 ± 0.62 | 0.22 ± 0.6 |
| Change at Week 24 | 0.43 ± 0.92 | 0.65 ± 0.96 | 0.17 ± 0.91 |
| Change at Week 36 | 0.62 ± 1.04 | 0.64 ± 1.07 | 0.02 ± 1.27 |
| Change at Week 48 | 0.54 ± 1.39 | 0.58 ± 1.22 | 0.28 ± 1.26 |
| Change at Week 60 | 0.72 ± 1.32 | 0.25 ± 1.09 | 0.38 ± 1.22 |
| Change at Week 72 | 1.05 ± 1.73 | 0.45 ± 1.34 | 0.22 ± 1.22 |
| Change at Week 84 | 0.72 ± 1.51 | 0.33 ± 1.42 | 0.23 ± 0.92 |
| Change at Week 96 | 0.49 ± 1.44 | 0.1 ± 1.49 | 0.52 ± 1.28 |
| Change at Week 104 | 0.42 ± 1.49 | 0.16 ± 1.37 | 0.88 ± 1.39 |
Sweat samples were collected using an approved collection device. Baseline was defined as the most recent measurement before intake of the first dose of study drug (Ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
| millimole per liter (mmol/L) | Ivacaftor Arm: Study 110 | Ivacaftor Arm: Study 111 | Ivacaftor Arm: Study 113 |
|---|---|---|---|
| Baseline | 60.9 ± 19.4 | 80.2 ± 22.8 | 55.7 ± 22.2 |
| Change at Week 2 | -19.3 ± 10.7 | -38.4 ± 27.5 | -4.5 ± 10.9 |
| Change at Week 24 | -13 ± 18.4 | -39.2 ± 27 | 1.1 ± 15.8 |
| Change at Week 48 | -13.5 ± 16.2 | -40.6 ± 26.1 | -1.9 ± 17.8 |
| Change at Week 104 | -13.7 ± 22.9 | -32.9 ± 26.8 | 5.4 ± 18.1 |
The CFQ-R is a validated participant reported outcome measuring health related quality of life for participants with CF. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health related quality of life. Baseline was defined as the most recent measurement before intake of the first dose of study drug (ivacaftor) in Study 112. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
| units on a scale | Ivacaftor Arm: Study 110 | Ivacaftor Arm: Study 111 | Ivacaftor Arm: Study 113 |
|---|---|---|---|
| Baseline | 68.6 ± 21.6 | 72.4 ± 20.3 | 65.9 ± 18.8 |
| Change at Week 2 | 5.5 ± 17.9 | 4.5 ± 17.5 | 13.2 ± 16.2 |
| Change at Week 12 | 11.6 ± 18 | 5.7 ± 18.5 | 13.5 ± 20 |
| Change at Week 24 | 6.7 ± 19 | 3.4 ± 18.7 | 8.5 ± 14.9 |
| Change at Week 36 | 12.1 ± 19.3 | 5.7 ± 13.8 | 7.9 ± 20.5 |
| Change at Week 48 | 9.5 ± 17.6 | 4.4 ± 13.2 | 11.4 ± 15.7 |
| Change at Week 60 | 7.1 ± 18.6 | 4.4 ± 10.9 | 8.6 ± 19.3 |
| Change at Week 72 | 10.4 ± 22.2 | 5.6 ± 11.8 | 8.6 ± 19 |
| Change at Week 84 | 10.5 ± 19.5 | 8.8 ± 14.1 | 4.9 ± 14.6 |
| Change at Week 96 | 8.8 ± 21.1 | 0 ± 9.5 | 9.4 ± 14.7 |
| Change at Week 104 | 9.2 ± 14 | 1.9 ± 8.8 | 19.9 ± 16 |
Pulmonary exacerbation events include those events which require treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms. The number of events were reported. Results were planned to be reported for Ivacaftor arm and were stratified by parent study 110, 111 and 113.
| pulmonary exacerbation events | Ivacaftor Arm: Study 110 | Ivacaftor Arm: Study 111 | Ivacaftor Arm: Study 113 |
|---|---|---|---|
| Number of Pulmonary Exacerbations Events | 47 | 30 | 6 |
SAE was defined as a medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, In-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event.
| participants | Observational Arm |
|---|---|
| Number of Participants With Serious Adverse Events (SAEs) in Observational Arm | 1 |
Collected over Day 1 up to Week 108 for Ivacaftor arm; up to 2 years for Observational arm (Study 112). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ivacaftor Arm | — | 27/121 (22.3%) | 117/121 (96.7%) |
| Observational Arm | — | 1/4 (25%) | — |
| Event | Ivacaftor Arm | Observational Arm |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 21/121 | 1/4 |
| GastroenteritisInfections and infestations | 2/121 | 0/4 |
| PneumoniaInfections and infestations | 2/121 | 0/4 |
| Influenza A virus test positiveInvestigations | 1/121 | 0/4 |
| Cardiomyopathy acuteCardiac disorders | 1/121 | 0/4 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/121 | 0/4 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/121 | 0/4 |
| Crohn's diseaseGastrointestinal disorders | 1/121 | 0/4 |
| Abdominal painGastrointestinal disorders | 1/121 | 0/4 |
| FlatulenceGastrointestinal disorders | 1/121 | 0/4 |
| Event | Ivacaftor Arm | Observational Arm |
|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 49/121 | — |
| CoughRespiratory, thoracic and mediastinal disorders | 41/121 | — |
| HeadacheNervous system disorders | 23/121 | — |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 22/121 | — |
| Sputum increasedRespiratory, thoracic and mediastinal disorders | 22/121 | — |
| NasopharyngitisInfections and infestations | 21/121 | — |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 18/121 | — |
| SinusitisInfections and infestations | 18/121 | — |
| PyrexiaGeneral disorders | 17/121 | — |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 17/121 | — |
| Age, Customized(participants) | Ivacaftor Arm | Observational Arm | Total |
|---|---|---|---|
| 6 to 11 years | 21 | 1 | 22 |
| 12 to 17 years | 11 | 1 | 12 |
| 18 years and over | 89 | 2 | 91 |
| Sex: Female, Male(Participants) | Ivacaftor Arm | Observational Arm | Total |
|---|---|---|---|
| Female | 61 | 3 | 64 |
| Male | 60 | 1 | 61 |
The record gives a start of Feb 2013, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →